Clopidogrel Bisulfate, a key pharmaceutical intermediate manufactured by companies like NINGBO INNO PHARMCHEM CO.,LTD., is a vital component in the fight against cardiovascular diseases. Understanding the science behind this compound, including its mechanism of action and therapeutic importance, is crucial for appreciating its role in modern medicine. As a premier Clopidogrel Bisulfate API manufacturer in China, we are committed to providing the highest quality materials to support these critical medical applications.

The primary function of Clopidogrel Bisulfate, identified by its CAS number 120202-66-6, is its ability to act as an antiplatelet agent. It irreversibly inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor, P2Y12. This inhibition prevents the activation of the glycoprotein IIb/IIIa complex, which is essential for platelet aggregation and thrombus formation. By blocking this pathway, Clopidogrel Bisulfate effectively reduces the risk of blood clots forming in arteries, which can lead to heart attacks, strokes, and other serious thrombotic events.

The therapeutic importance of Clopidogrel Bisulfate cannot be overstated. It is widely prescribed for patients with acute coronary syndrome (ACS), following myocardial infarction or stroke, and for individuals with peripheral arterial disease. The consistent demand for this API highlights the necessity of reliable Clopidogrel Bisulfate suppliers. NINGBO INNO PHARMCHEM CO.,LTD. understands the critical nature of this compound and ensures that every batch of Clopidogrel Bisulfate meets stringent purity and efficacy standards.

When considering the purchase of Clopidogrel Bisulfate, understanding the Clopidogrel Bisulfate price and the overall value proposition offered by a manufacturer is essential. Our commitment to scientific excellence and robust manufacturing processes means that when you buy Clopidogrel Bisulfate from us, you are investing in a product that supports life-saving therapies. We pride ourselves on being a trusted source for high-quality pharmaceutical intermediates, contributing to the global effort to improve cardiovascular health.